<DOC>
	<DOCNO>NCT02574663</DOCNO>
	<brief_summary>This Phase 1 multi-center study assess safety efficacy TGR-1202 single agent combination nab-paclitaxel + gemcitabine FOLFOX patient select relapsed refractory solid tumor .</brief_summary>
	<brief_title>TGR-1202 Alone Combination With Either Nab-paclitaxel + Gemcitabine With FOLFOX Patients With Select Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description>TGR-1202 evaluate alone combination nab-paclitaxel + gemcitabine FOLFOX patient adenocarcinoma pancreas , adenocarcinoma colon , rectum , gastric GE junction cancer , GI Stromal Tumor ( GIST ) relapse refractory prior treatment .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>Histologically confirm : 1. adenocarcinoma pancreas ( pancreatic cancer ) 2. adenocarcinoma colon rectum ( colorectal cancer ) 3. adenocarcinoma gastric ( gastric cancer ) 4. esophageal cancer 5. gastrointestinal stromal tumor ( GIST ) Relapsed refractory disease Measurable lesion RECIST 1.1 Known Hepatitis B , C HIV infection Previous therapy drug inhibits PI3K pathway Antitumor therapy within 21 day study Day 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>